Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality
COVID-19 pneumonia and subsequent respiratory failure is causing an immense strain on intensive care units globally. Early prediction of severe disease enables clinicians to avoid acute respiratory distress syndrome (ARDS) development and improve management of critically ill patients. The soluble re...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 March 2021
|
| In: |
Annals of intensive care
Year: 2021, Volume: 11, Pages: 1-13 |
| ISSN: | 2110-5820 |
| DOI: | 10.1186/s13613-021-00836-2 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13613-021-00836-2
|
| Author Notes: | Adeline Lim, Aleksandar Radujkovic, Markus A. Weigand and Uta Merle |
| Summary: | COVID-19 pneumonia and subsequent respiratory failure is causing an immense strain on intensive care units globally. Early prediction of severe disease enables clinicians to avoid acute respiratory distress syndrome (ARDS) development and improve management of critically ill patients. The soluble receptor of advanced glycation endproducts (sRAGE) is a biomarker shown to predict ARDS. Although sRAGE level varies depending on the type of disease, there is limited information available on changes in sRAGE levels in COVID-19. Therefore, sRAGE was measured in COVID-19 patients to determine sRAGE level variation in COVID-19 severity and to examine its ability to predict the need for mechanical ventilation (MV) and mortality in COVID-19. |
|---|---|
| Item Description: | Gesehen am 14.04.2021 |
| Physical Description: | Online Resource |
| ISSN: | 2110-5820 |
| DOI: | 10.1186/s13613-021-00836-2 |